CurrentColorado Rocky Mountain Health PlansPolicy N/A

Cysteamine ophthalmic (Cystaran, Cystadrops) prior authorization

Prior authorization and reauthorization requirements for Cystaran (cysteamine 0.44% ophthalmic solution) and Cystadrops (cysteamine 0.37% ophthalmic solution) for treatment of corneal cystine crystal accumulation in patients with cystinosis.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyCysteamine ophthalmic (Cystaran, Cystadrops) prior authorization

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 15, 2026

Next Review DateNov 25, 2025

Key ActionSubmit documentation of diagnosis and clinical response to cysteamine ophthalmic therapy to obtain initial authorization or reauthorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Cystaran, CystadropsMedications

12 monthsAuth duration

Prior Auth/NotificationProgram type

Coverage Criteria for Cysteamine Ophthalmic

inv-01: Initial Authorization

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

There are no conditions explicitly labeled as ‘‘not medically necessary’’ within this policy. The Additional Clinical Rules section clarifies that approvals may be made based on prior claim or medication history and that program-level rules (such as supply limits) can affect approvals, but the document does not specify any NMN scenarios.

Provider Actions and Authorization Workflow

Prior Authorization

Initial Authorization — Required Documentation & Diagnostic Criteria

Initial authorization required: Cystaran or Cystadrops will be approved when documentation shows a diagnosis of cystinosis and treatment is for corneal cystine crystal accumulation. Authorization is issued for 12 months.

Diagnosis: cystinosis
Indication: treatment of corneal cystine crystal accumulation
Authorization duration: 12 months

Prior Authorization

Reauthorization — Clinical Response Required

Reauthorization requires documentation of a positive clinical response to therapy. Reauthorizations are issued for 12 months. Note that state mandates, federal regulatory requirements, and the member-specific benefit plan may affect coverage; other policies and utilization management programs may also apply.

Documentation: positive clinical response to therapy
Authorization duration: 12 months
Potential modifiers: state mandates, federal requirements, member benefit plan, other UM programs

Step Therapy

No step therapy requirements specified for Cystaran or Cystadrops in the source material.

Documentation Required

Required Documentation

Documentation required for both initial authorization and reauthorization includes: diagnosis of cystinosis, indication that treatment is for corneal cystine crystal accumulation (initial), and documentation of positive clinical response (reauthorization). Also note that automated approval processes may approve based on claim/medication history, ICD-10 diagnosis codes, and claim logic; supply limits may apply. State mandates and member plan coverage may impact requirements.

Required documentation: diagnosis of cystinosis
Initial therapy: documentation that treatment is for corneal cystine crystal accumulation
Reauthorization: documentation of positive clinical response
Automated approvals: previous claim/medication history, diagnosis codes (ICD-10), and/or claim logic may be used
Supply limits may apply
State mandates, federal requirements, and member-specific benefit plan may affect coverage

Denial Risk

Denial Triggers & Approval Variability

Denial risk triggers include absence of required documentation (diagnosis, indication, or evidence of clinical response), exceeding supply limits, or lack of information that prevents automated approval processes from validating prior therapy/claims.

Missing diagnosis or indication
No documentation of positive clinical response on reauthorization
Supply limits exceeded
Insufficient claim/medication history or diagnosis codes to support automated approval

Background

Cystaran (cysteamine 0.44% ophthalmic solution) and Cystadrops (cysteamine 0.37% ophthalmic solution) are topical cystine‑depleting agents indicated for treatment of corneal cystine crystal accumulation in patients with cystinosis. The coverage criteria require documentation of a diagnosis of cystinosis and treatment for corneal cystine crystal accumulation for initial approval, and documentation of a positive clinical response to cysteamine ophthalmic therapy for reauthorization. Authorizations are issued for 12 months when criteria are met. Additional clinical rules note that UnitedHealthcare may use prior claim/medication history, diagnosis codes, or automated processes to approve initial or reauthorization requests, and that supply limits may apply.

Definitions

Corneal cystine crystal accumulation — definition and clinical context

DefinitionDeposition of cystine crystals in the cornea associated with the systemic rare disease cystinosis.

Clinical relevanceLeads to vision symptoms and is the target condition for topical cysteamine therapy (Cystaran 0.44% and Cystadrops 0.37%).

Indicated treatmentsTopical cysteamine ophthalmic solutions (Cystaran and Cystadrops) are indicated to treat corneal cystine crystal accumulation.

Associated diseaseOccurs in patients with cystinosis, a systemic lysosomal storage disorder characterized by cystine accumulation.

Purpose of therapyCysteamine ophthalmic formulations deplete corneal cystine crystals to prevent progression and improve ocular outcomes.